This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Vertex Pharmaceuticals Inc (VRTX)

NASDAQ: Health Care

Company Cash Flow
Dec 2014 Dec 2013 Dec 2012 Dec 2011
Cash Flow From Operating Activities
Net Income (Loss) 0.00 -687.55M -51.14M 41.18M
Operating Gains/Losses n.a. 0.00 390.00K 16.86M
Extraordinary Gains / Losses n.a. 0.00 0.00 0.00
(Increase) Decrease In Receivables n.a. 53.36M 39.91M -170.61M
(Increase) Decrease in Inventories n.a. 7.14M -29.92M -111.39M
(Increase) Decrease In Other Current Assets n.a. 0.00 0.00 0.00
(Decrease) Increase In Payables n.a. -49.23M 14.89M 37.47M
(Decrease) Increase In Other Current Liabilities 0.00 48.75M 17.87M 125.62M
(Increase) Decrease In Other Working Capital n.a. -53.01M -44.28M -72.44M
Other Non-Cash Items n.a. 877.72M 257.52M 232.82M
Net Cash From Continuing Operations n.a. -51.57M 267.84M 143.74M
Net Cash From Discontinued Operations n.a. 0.00 0.00 0.00
Cash Provided By Investing Activities
Net Cash From Total Operating Activities 0.00 -51.57M 267.84M 143.74M
Sale of Property, Plant & Equipment n.a. 0.00 0.00 0.00
Cash Used for Investing Activities
Sale of Short-Term Investments n.a. 2.35B 1.37B 1.02B
Purchases of Property, Plant & Equipment 0.00 -51.39M -71.14M -94.60M
Acquisitions n.a. 0.00 0.00 0.00
Purchases of Short-Term Investments n.a. -2.41B -1.71B -721.54M
Other Cash from Investing Activities 0.00 61.39M -16.78M 12.51M
Cash Provided by Financing Activities
Net Cash From Investing Activities 0.00 -54.13M -425.82M 212.41M
Issuance of Debt 0.00 0.00 0.00 0.00
Cash Used for Financing Activities
Issuance of Capital Stock n.a. 265.88M 191.72M 124.86M
Repayment of Long-Term Debt 0.00 -83.74M -21.49M -250.00M
Repurchase of Capital Stock 0.00 0.00 0.00 0.00
Payment of Cash Dividends 0.00 0.00 0.00 0.00
Other Financing Charges, Net n.a. -1.25M 1.97M 900.00K
Net Cash From Financing Activities 0.00 180.88M 172.20M -124.24M
Effect of Exchange Rate Changes 0.00 4.71M -141.00K 214.00K
Net Change in Cash & Cash Equivalents 0.00 79.89M 14.09M 232.12M
VRTX News

VRTX Vertex Pharmaceuticals Inc

Analysts Ratings for VRTX

Rating Current 1-Mo Ago 2-Mo Ago 3-Mo Ago
Strong Buy 8 8 8 8
Moderate Buy 1 1 1 1
Hold 9 5 5 6
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
GET VRTX ANALYST REPORT

Brokerage Partners

VRTX Chatter

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Real Money Pro

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Trifecta Stocks

Trifecta Stocks analyzes over 4,000 equities weekly to find the elite 1% of stocks that pass rigorous quantitative, fundamental and technical tests.

Product Features:
  • Model portfolio
  • Trade alerts
  • Recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
Stocks Under $10

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Dividend Stock Advisor

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Growth Seeker

Bryan Ashenberg, using sophisticated stock screening and fundamental research, identifies potentially explosive small and mid-cap stocks.

Product Features:
  • Model portfolio
  • Small-cap and mid-cap focus
  • Intraday trade alerts
  • Weekly roundups
Options Profits

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
Top Rated Stocks Top Rated Funds Top Rated ETFs